GIP | Jotup

EQS-News: Søren Skou appointed as Chair of the Advisory Board of Skyborn Renewables

Retrieved on:

Wednesday, April 10, 2024

Partnership, GIP, Global Infrastructure Partners, Advisory board, Growth, Acquisition

Søren Skou, the former Chief Executive Officer (CEO) of A.P.

Key Points:

Søren Skou, the former Chief Executive Officer (CEO) of A.P.
Moller-Maersk (“Maersk”), has joined Skyborn Renewables (“Skyborn”) as Chair of the Advisory Board.
“We are delighted to welcome Søren to Skyborn.
“I am very pleased to join Skyborn,” said Skou.

EQS-News: Skyborn Announces Leadership Transition

Retrieved on:

Wednesday, April 10, 2024

Shell plc, Advisory board, Growth, Entrepreneurship, Diesel exhaust fluid, Wind, Carbon, Happiness, E.ON, GIP, Marketing

Thomas will continue in an advisory capacity, serving as a counselor to both the Advisory Board and Patrick to enable an effective transition for Skyborn.

Key Points:

Thomas will continue in an advisory capacity, serving as a counselor to both the Advisory Board and Patrick to enable an effective transition for Skyborn.
"We thank Thomas for his leadership in navigating the challenges faced by Skyborn and its offshore wind developer peers over the past year, in building Skyborn into a stronger, more resilient company and for his support in ensuring a seamless transition.
Patrick Lammers brings strong commercial, customer, and digital experience to Skyborn, as it continues to establish itself as a leader for offshore wind’s role in the energy transition.
I look forward to transitioning the leadership of Skyborn to Patrick, who I am confident will continue the growth and development of Skyborn into one of the world’s leading offshore wind platforms.”

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Retrieved on:

Wednesday, March 20, 2024

SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update.

Key Points:

ET / 1:30 p.m. PT -
SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update.
In February 2024, Rani announced RT-111 achieved high bioavailability and was well-tolerated, with no serious adverse events in humans, in a Phase 1 study.
In December 2023, Rani announced preclinical data demonstrating the transenteric delivery of an incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study.
In October 2023, Rani announced preclinical data from a 60-day, repeat oral-administration GLP safety study of the RaniPill capsule in healthy animals.

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Retrieved on:

Friday, March 8, 2024

Molecule, Therapy, IPF, SAN, Research, Investment, Obesity, Apelin, Idiopathic pulmonary fibrosis, Growth, GIPR, GIP, A1C, Interim, Safety, GPCR, G&A, Glycated hemoglobin, Pharmaceutical industry

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent corporate achievements.

Key Points:

“In 2023 we demonstrated clear proof-of-concept with our lead GLP-1 receptor agonist, GSBR-1290, for obesity and type 2 diabetes.
This study is fully enrolled and data are expected in the latter half of the second quarter of 2024.
The Company plans to initiate a global Phase 2b obesity study of GSBR-1290 in the fourth quarter of 2024.
Net Loss: Net loss for the fourth quarter of 2023 totaled $24.5, with non-cash stock-based compensation expense of $2.1 million, compared to $11.9 million for the fourth quarter of 2022 with non-cash stock-based compensation expense of $0.6 million.

Global Infrastructure Partners Announces Total $2.1 Billion Final Closing of Its Inaugural Emerging Markets Fund

Retrieved on:

Tuesday, March 5, 2024

Banking, Asset Management, Professional Services, Finance, Market, Investment, Emerging market, GIP, Global Infrastructure Partners, Fund, Insurance, Pension fund

Global Infrastructure Partners (GIP), a leading infrastructure investor, announced today that GIP Emerging Markets Fund I (“GIP EM” or “the Fund”) has completed fundraising for aggregate committed capital of more than $2.1 billion.

Key Points:

Global Infrastructure Partners (GIP), a leading infrastructure investor, announced today that GIP Emerging Markets Fund I (“GIP EM” or “the Fund”) has completed fundraising for aggregate committed capital of more than $2.1 billion.
The Fund garnered significant support from GIP’s existing investor base while also attracting new investors with a specific interest in emerging markets infrastructure.
GIP Emerging Markets Fund I is a dedicated emerging markets-focused fund that extends GIP’s Flagship equity strategy to opportunities in 11 Target Countries in Asia and Latin America.
“We are extremely gratified by the confidence that EM Fund investors have placed in us,” said James Amine, GIP Partner and Head of Emerging Markets.

Eversource Energy Announces Pathway to Fully Exit its Offshore Wind Investments Pursuant to Agreement with Global Infrastructure Partners to Sell Revolution Wind and South Fork Wind Projects

Retrieved on:

Tuesday, February 13, 2024

Eversource Energy (NYSE: ES) (“Eversource”) today announced it has executed a definitive agreement to sell its 50 percent ownership share in South Fork Wind and Revolution Wind to Global Infrastructure Partners (GIP).

Key Points:

Eversource Energy (NYSE: ES) (“Eversource”) today announced it has executed a definitive agreement to sell its 50 percent ownership share in South Fork Wind and Revolution Wind to Global Infrastructure Partners (GIP).
The agreement covers Eversource’s 50 percent share in the 132-megawatt South Fork Wind project and the 704-megawatt Revolution Wind project.
Eversource is expected to enter into a separate construction management agreement as a contractor to Revolution Wind to complete the onshore work that is currently underway.
Eversource will maintain its previously announced tax equity investment in South Fork Wind.

Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery

Retrieved on:

Tuesday, February 6, 2024

REDWOOD CITY, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced a publication in Nature Communications from a study led by Weill Cornell Medicine showing Seer’s Proteograph workflow to potentially unveil novel proteogenomic insights into genetics-based drug and biomarker discovery for precision medicines. Designed to address the challenges with affinity-based proteomic approaches for protein quantitative trait loci (pQTL) studies, the scalable, high-resolution Proteograph workflow enables scientists to link genetic variation with protein abundance with peptide level resolution.

Key Points:

The study found 184 PAVs in 137 genes, confirmed by their variant peptides in mass spectrometry data, known as MS-PAV.
Most MS-PAVs were aligned with known genetic markers (cis-pQTLs), validating the target specificity of the method.
Seer's approach provides customers with unparalleled insights into drug response analysis, drug discovery, patient stratifications for clinical studies, and precision medicine.
“At Seer, we offer researchers a new method for pQTL mapping and a deeper understanding of proteins and peptides for large-scale proteogenomic studies.”

EQS-News: Infineon with robust Q1 FY 2024. Market environment outside automotive remains weak. Weaker currency and markets are leading to an adjustment of FY 2024 outlook

Retrieved on:

Tuesday, February 6, 2024

PSS, Kulim District, Research, ROCE, Internet, GIP, Investment, ATV, Power, Acquisition, Silicon, Depreciation, Free cash flow, Connected, EST, Cash flow, Webcast, CSS, Video game

The Segment Result in the first quarter of the 2024 fiscal year amounted to €831 million, compared with €1,044 million in the prior quarter.

Key Points:

The Segment Result in the first quarter of the 2024 fiscal year amounted to €831 million, compared with €1,044 million in the prior quarter.
The first-quarter Non-Segment Result was a net loss of €129 million, compared with a net loss of €132 million in the prior quarter.
Operating profit for the first quarter of the 2024 fiscal year reached €702 million, compared with €912 million in the previous three-month period.
The tax expense in the first quarter of the 2024 fiscal year amounted to €134 million, compared with €163 million in the prior quarter.

New ICON Survey Highlights Importance of Combination Therapies in Future Obesity Treatment

Retrieved on:

Wednesday, January 24, 2024

The majority of respondents believe the future of obesity therapies lies in trials that are designed to measure more than one outcome.

Key Points:

The majority of respondents believe the future of obesity therapies lies in trials that are designed to measure more than one outcome.
There is much overlap between obesity and co-morbidities such as diabetes, steatosis (fatty liver), and cardiovascular disease, and in line with this, most respondents (64%) felt combination therapies would be the primary focus of future research.
Obesity is a growing health concern worldwide, with at least 2.8 million people dying each year because of the disease1.
There is more to examine on the implications of obesity as a risk factor across the disease spectrum and how it may impact treatment, drug development and clinical trials for obesity.

EnLink Midstream Expands Common Unit Repurchase Authorization, Increases Quarterly Distribution, and Updates Financial Policy

Retrieved on:

Tuesday, January 16, 2024

GIP, Global Infrastructure Partners, Policy, Sale, Webcast, Interest, Cryptocurrency

DALLAS, Jan. 16, 2024 /PRNewswire/ -- EnLink Midstream, LLC (NYSE: ENLC) (EnLink) announced today that the EnLink Board of Directors (Board) completed its expanded 2023 common unit repurchase authorization of $250 million, authorized a 2024 common unit repurchase plan, increased its quarterly distribution for the fourth quarter of 2023 by approximately 6%, and updated EnLink's financial policy to reflect a long-term leverage target of 3.5x debt-to-EBITDA.

Key Points:

DALLAS, Jan. 16, 2024 /PRNewswire/ -- EnLink Midstream, LLC (NYSE: ENLC) (EnLink) announced today that the EnLink Board of Directors (Board) completed its expanded 2023 common unit repurchase authorization of $250 million, authorized a 2024 common unit repurchase plan, increased its quarterly distribution for the fourth quarter of 2023 by approximately 6%, and updated EnLink's financial policy to reflect a long-term leverage target of 3.5x debt-to-EBITDA.
In November, the Board increased the 2023 common unit repurchase authorization by $50 million to $250 million.
EnLink fully executed the expanded 2023 common unit repurchase program, including approximately $42 million of common units repurchased from Global Infrastructure Partners (GIP), pursuant to our 2023 Unit Repurchase Agreement, which will settle on February 19, 2024.
GIP will also participate in the 2024 unit repurchases through its execution of a Unit Repurchase Agreement for 2024.